Press Room


British Columbia Breast Cancer Patients Gain Access to Oncotype DX®

New Research Shows Genomic Testing Changes Chemotherapy Treatment Decisions

Media Coverage

The Oncotype DX assay has recently been featured in many Canadian national and local newspapers. Below are some stories which may be of interest to you:

The Globe and Mail
Gene expression profiling test expands to assess colon and prostate cancers June 22, 2014
Article discusses how genomics and the Oncotype DX test can be incorporated in breast, colon and prostate cancer care.

Ontario begins funding breast-cancer test - March 8, 2010
Ontario has begun funding a molecular test that can tell a breast-cancer patient whether they can safely skip chemotherapy.

The Oncotype DX cancer test - December 4, 2009
An overview of the Oncotype DX Breast Cancer Assay from Genomic Health®.

Alberta Health Funds Breast Cancer Test

Global News National
Genetic testing prompts new style of preventive health Care - April 13, 2012
Breast cancer survivor Coree Hanczyk shares her story, explains the role of the Oncotype DX test in her treatment decision.

Global TV Calgary
Judge calls for province to fund cancer test - January 29, 2013
Based on her own breast cancer experience, Alberta patient encourages public funding for genomic testing in the province.

Cancer Research: New Technologies to Know - October 2012
Could genomic testing be the crystal ball of cancer treatments? Story highlights how the Oncotype DX breast cancer test can help guide chemotherapy treatment decisions.

Contact Us

Get in Touch
Making cancer care smarter.™

This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By continuing to use this website, you agree that we can place these types of cookies on your device. For more information, please read our privacy policy.